Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

被引：97

作者：

Aalders, Kim C. ^{[1
]}

Tryfonidis, Konstantinos ^{[1
]}

Senkus, Elbieta ^{[2
]}

Cardoso, Fatima ^{[3
]}

机构：

[1] European Org Res Treatment Canc, Dept Med, Brussels, Belgium

[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

[3] Champalimaud Canc Ctr, Breast Unit, Lisbon, Portugal

来源：

CANCER TREATMENT REVIEWS | 2017年 / 53卷

关键词：

Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BEVACIZUMAB PLUS PACLITAXEL; OPEN-LABEL; 1ST-LINE TREATMENT; NEOADJUVANT CHEMOTHERAPY; TUMOR-CELLS; FACTOR VEGF;

D O I：

10.1016/j.ctrv.2016.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：98 / 110

页数：13

共 50 条

[41] Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
Teresa Mele
Daniele Generali
Stephen Fox
Maria Pia Brizzi
Alessandra Bersiga
Manuela Milani
Giovanni Allevi
Simone Bonardi
Sergio Aguggini
Marco Volante
Luigi Dogliotti
Alberto Bottini
Adrian Harris
Alfredo Berruti
Breast Cancer Research and Treatment, 2010, 123 : 795 - 804
[42] Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment
Mehta, Shaveta
Hughes, Nick P.
Li, Sonia
Jubb, Adrian
Adams, Rosie
Lord, Simon
Koumakis, Lefteris
van Stiphout, Ruud
Padhani, Anwar
Makris, Andreas
Buffa, Francesca M.
Harris, Adrian L.
EBIOMEDICINE, 2016, 10 : 109 - 116
[43] Anti-angiogenic therapies for gastric cancer
Hironaka, Shuichi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 208 - 217
[44] Anti-Angiogenic Cancer Therapy Updates
Ali, A. M.
Toi, M.
Ueno, T.
CURRENT MOLECULAR MEDICINE, 2009, 9 (08) : 954 - 966
[45] Anti-Angiogenic Peptides for Cancer Therapeutics
Rosca, Elena V.
Koskimaki, Jacob E.
Rivera, Corban G.
Pandey, Niranjan B.
Tamiz, Amir P.
Popel, Aleksander S.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (08) : 1101 - 1116
[46] Anti-angiogenic treatment and colorectal cancer
Andre, Thierry
Tournigand, Christophe
Abbas, Fadi
Louvet, Christophe
de Gramont, Airnery
BULLETIN DU CANCER, 2007, 94 : S211 - S219
[47] Future options of anti-angiogenic cancer therapy
Yihai Cao
ChineseJournalofCancer, 2016, 35 (02) : 66 - 74
[48] Propranolol potentiates the anti-angiogenic effects and antitumor efficacy of chemotherapy agents: implication in breast cancer treatment
Pasquier, Eddy
Ciccolini, Joseph
Carre, Manon
Giacometti, Sarah
Fanciullino, Raphaelle
Pouchy, Charlotte
Montero, Marie-Pierre
Serdjebi, Cindy
Kavallaris, Maria
Andre, Nicolas
ONCOTARGET, 2011, 2 (10) : 797 - 809
[49] The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment
Li, Ding
Finley, Stacey D.
INTEGRATIVE BIOLOGY, 2018, 10 (04) : 253 - 269
[50] Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer
Goel, Gaurav
Chauhan, Aman
Hosein, Peter J.
CURRENT COLORECTAL CANCER REPORTS, 2016, 12 (05) : 232 - 240

← 1 2 3 4 5 →